All In Biotech

Drug Trial Radar · NCT06775730

A Drug-Drug Interaction Study of S-217622 With Combined Oral Contraceptives in Healthy Adult Female Participants

A Phase 1 Drug-Drug Interaction Study of S-217622 With Combined Oral Contraceptives in Healthy Adult Female Participants

Last checked: Nov 20, 2026Latest source record: May 4, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

24

Actual

Start

Dec 30, 2024

Primary completion

Apr 3, 2025

Study completion Apr 3, 2025

Sponsor

Lead sponsor
ShionogiIndustry
Sponsor type
Industry
First posted
Jan 15, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years, up to 35 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to examine the potential for drug-drug interactions.

Conditions

  • Healthy Adult Female Participants

Interventions

  • EnsitrelvirDrug

    Ensitrelvir will be administered per schedule specified in the arm description.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum Plasma Concentration (Cmax) of Ethinyl Estradiol (EE)Time frame: Predose and up to 24 hours postdose on Days 19, 20, and 24
  2. Cmax of Drospirenone (DRSP)Time frame: Predose and up to 24 hours postdose on Days 19, 20, and 24
  3. Time to Reach Cmax (Tmax) of EETime frame: Predose and up to 24 hours postdose on Days 19, 20, and 24
  4. Tmax of DRSPTime frame: Predose and up to 24 hours postdose on Days 19, 20, and 24
  5. Area Under the Plasma Concentration-time Curve Over the Dosing Interval (AUC0-τ) of EETime frame: Predose and up to 24 hours postdose on Days 19, 20, and 24
  6. AUC0-τ of DRSPTime frame: Predose and up to 24 hours postdose on Days 19, 20, and 24

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Early Phase Clinical Unit Los Angeles

    Glendale, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.